Short answer
ALUMIS INC. (ALMS) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $2M (down 90.0% year over year) with net income of −$93M.
Q1 2026 key financials · XBRL
- Revenue
- $2M
- −90.0% YoY
- Net income
- −$93M
- +6.0% YoY
- Operating margin
- -5652.4%
- EPS (diluted)
- −$0.74
- +59.3% YoY
Source: XBRL data from the ALUMIS INC. (ALMS) Q1 2026 10-Q on SEC EDGAR. USD.
ALUMIS INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved or product sales generated
- Net loss $93.1M vs $99.0M YoY; profitability margins not disclosed
- Envu strongest development program; positive Phase 3 PsO topline results reported in Q1 2026
- Cash deployment $324.4M net proceeds from January public offering; no ATM shares sold by March 31
- NDA submission for envu in PsO planned for second half of 2026; SLE topline results expected Q3 2026
Risk Factors
- New $300.0 million Cantor sales agreement creates potential shareholder dilution
- Net loss $93.1 million and accumulated deficit $994.9 million heighten financing dependence
- Phase 2b SLE trial enrollment remains challenging because active disease is required at screening
- FDA or foreign regulators may impose additional trial requirements, delaying envu development
- Competitor therapies may reduce clinical-trial enrollment and envu market opportunity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ALUMIS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.